Mast Therapeutics, Inc. (NASDAQ:SVRA) had its price target lowered by stock analysts at Roth Capital from $40.00 to $32.00 in a report released on Tuesday. The brokerage currently has a “buy” rating on the stock. Roth Capital’s price objective points to a potential upside of 243.72% from the company’s current price.

Several other analysts also recently weighed in on the company. Canaccord Genuity reiterated a “buy” rating and set a $18.00 target price on shares of Mast Therapeutics in a research report on Monday, July 17th. Zacks Investment Research upgraded Mast Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective for the company in a report on Friday, September 8th. Jefferies Group LLC started coverage on Mast Therapeutics in a report on Friday, September 22nd. They issued a “buy” rating and a $20.00 price objective for the company. Finally, JMP Securities started coverage on Mast Therapeutics in a report on Monday, September 11th. They issued an “outperform” rating and a $20.00 price objective for the company. Five analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $21.30.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/mast-therapeutics-inc-svra-price-target-cut-to-32-00/1673690.html.

In related news, Director Yuri Pikover bought 50,000 shares of the business’s stock in a transaction on Friday, October 27th. The shares were bought at an average price of $7.85 per share, for a total transaction of $392,500.00. Following the completion of the purchase, the director now directly owns 150,000 shares of the company’s stock, valued at $1,177,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.93% of the stock is owned by insiders.

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.